These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20496264)

  • 1. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.
    Rosevear HM; Lightfoot AJ; Griffith TS
    Curr Opin Investig Drugs; 2010 Jun; 11(6):688-98. PubMed ID: 20496264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
    Bajaj M; Heath EI
    Expert Opin Biol Ther; 2011 Nov; 11(11):1519-24. PubMed ID: 21877997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling.
    Zoog SJ; Ma CY; Kaplan-Lefko PJ; Hawkins JM; Moriguchi J; Zhou L; Pan Y; Hsu CP; Friberg G; Herbst R; Hill J; Juan G
    Cytometry A; 2010 Sep; 77(9):849-60. PubMed ID: 20623688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.
    Kaplan-Lefko PJ; Graves JD; Zoog SJ; Pan Y; Wall J; Branstetter DG; Moriguchi J; Coxon A; Huard JN; Xu R; Peach ML; Juan G; Kaufman S; Chen Q; Bianchi A; Kordich JJ; Ma M; Foltz IN; Gliniak BC
    Cancer Biol Ther; 2010 Apr; 9(8):618-31. PubMed ID: 20150762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL-receptor antibodies as a potential cancer treatment.
    Buchsbaum DJ; Forero-Torres A; LoBuglio AF
    Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2.
    Marini P
    Curr Opin Mol Ther; 2006 Dec; 8(6):539-46. PubMed ID: 17243490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
    Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
    Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
    Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
    J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
    Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
    Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting death-receptors in radiation therapy.
    Niemöller O; Belka C
    Results Probl Cell Differ; 2009; 49():219-39. PubMed ID: 19582410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.
    Giordano S
    Curr Opin Mol Ther; 2009 Aug; 11(4):448-55. PubMed ID: 19649990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL death receptors and cancer therapeutics.
    Huang Y; Sheikh MS
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
    Zhang L; Zhang X; Barrisford GW; Olumi AF
    Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
    Vulfovich M; Saba N
    Curr Opin Mol Ther; 2005 Oct; 7(5):502-10. PubMed ID: 16248286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
    Ashkenazi A; Holland P; Eckhardt SG
    J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting TRAIL death receptors.
    Oldenhuis CN; Stegehuis JH; Walenkamp AM; de Jong S; de Vries EG
    Curr Opin Pharmacol; 2008 Aug; 8(4):433-9. PubMed ID: 18625341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.